Shilpa Medicare Secures Regulatory Approval for Innovative Liver Treatment

Shilpa Medicare Ltd has achieved a significant milestone in its pharmaceutical portfolio. The Central Drugs Standard Control Organisation (CDSCO) has recommended marketing authorization for the company's treatment for Non-Alcoholic Fatty Liver Disease (NAFLD). Additionally, Shilpa Medicare has received CDSCO approval for Nor Ursodeoxycholic Acid tablets. This dual regulatory success positions the company to enter the growing market for liver disease treatments. The approval of Nor Ursodeoxycholic Acid tablets, in particular, could provide a new option for patients suffering from liver disorders. These developments are expected to strengthen Shilpa Medicare's position in the pharmaceutical industry and potentially boost its revenue streams in the coming quarters.

Source: Reuters